The Phase I award worth $375,000 will be directed by the National Institute of Neurological Disorders and Stroke.
Winston president and CEO Joel Bernstein said the use of TRPV-1 modulators in treating neuropathic disease is a unique approach in the area, and the SBIR grant gives an opportunity to further investigate the use of this class of medications.
"The availability of an effective and safe treatment, i.e., without systemic effects or drug interactions, would fill an important unmet medical need in the treatment of PHN of the TN," Bernstein added.